SAB Biotherapeutics, Inc. (SABS) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
SAB Biotherapeutics, Inc. (SABS) Earnings Overview
As of November 8, 2026, SAB Biotherapeutics, Inc. (SABS) reported trailing twelve-month net income of -$81M, reflecting +78.5% year-over-year growth. The company earned $-0.86 per diluted share over the past four quarters.
Looking at the long-term picture, SABS's historical earnings data spans multiple years. The company achieved its highest annual net income of $20M in fiscal 2020.
SAB Biotherapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$538M net income), ARGX (N/A net income, 31.1% margin), HALO ($485M net income, 22.7% margin), SABS has comparable earnings metrics. Compare SABS vs IMVT →
SABS Earnings vs Peers
Earnings metrics vs comparable public companies
SABS Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $13M | +138.9% | -$49M | $-0.79 | - | - |
| 2024 | -$34M | +19.2% | -$43M | $-3.68 | -2579.0% | -3244.9% |
| 2023 | -$42M | -125.1% | -$38M | $-7.64 | -1884.5% | -1700.5% |
| 2022 | -$19M | -9.3% | -$29M | $-4.31 | -78.4% | -121.0% |
| 2021 | -$17M | -185.2% | -$13M | $-6.30 | -28.2% | -22.0% |
| 2020 | $20M | +323.9% | $21M | $7.45 | 36.4% | 37.2% |
| 2019 | -$9M | - | -$9M | $-0.22 | -261.1% | -252.0% |
Download Data
Export SABS earnings history in CSV or JSON format
Free sign-in required to download data
SABS Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SABS — Frequently Asked Questions
Quick answers to the most common questions about buying SABS stock.
What is SABS earnings per share (EPS)?
SABS trailing twelve-month (TTM) diluted EPS is $-0.86, reflecting +78.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is SAB Biotherapeutics, Inc.'s net income?
SAB Biotherapeutics, Inc. (SABS) trailing twelve-month net income is $-81M as of 2025. Earnings grew +78.5% year-over-year.
Is SABS profitable?
SABS is not currently profitable on a TTM basis, reporting a net loss of $-81M. Net margin is N/A. Investors should monitor for a return to profitability.
What is SABS's earnings growth rate?
SABS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are SABS's profit margins?
SAB Biotherapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is +15.0%.
Is SABS growing earnings?
Yes, SABS earnings are accelerating — EPS growth of +78.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-81M. Earnings momentum is strengthening.
What was SABS's best earnings year?
SAB Biotherapeutics, Inc.'s highest annual net income on record is $20M, achieved in fiscal year 2020. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were SABS's earnings last quarter?
SABS's most recent reported quarter was Q3 2026. Net income was $-22M with diluted EPS of $-0.24. For a full breakdown of all quarters, see the quarterly earnings table on this page.